Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Below 50-Day Moving Average – What’s Next?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $4.05 and traded as low as $1.48. Aldeyra Therapeutics shares last traded at $1.52, with a volume of 1,278,933 shares changing hands.

Aldeyra Therapeutics News Summary

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: Recent company context — Aldeyra reported a fiscal quarter EPS of ($0.11) that modestly beat estimates, but the company remains loss‑making (projected FY EPS -0.92). Trading has been light vs. average volume and the stock sits nearer its 52‑week low than its high, which can amplify negative news moves.
• Negative Sentiment: Rosen Law Firm filed a class action on behalf of Aldeyra purchasers (class period Nov 3, 2023–Mar 16, 2026) and is soliciting lead plaintiff candidates. ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
• Negative Sentiment: Faruqi & Faruqi, LLP is investigating claims and reminding investors of the May 29, 2026 deadline to seek lead‑plaintiff status, increasing the likelihood of consolidated litigation activity. ALDX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
• Negative Sentiment: The Schall Law Firm has issued a notice about the suit alleging violations of Securities Exchange Act provisions for the same class period and is soliciting clients to contact the firm. ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: Multiple other plaintiff firms (Wolf Haldenstein, The Gross Law Firm, Levi & Korsinsky, Robbins LLP, DJS Law Group and others) have filed notices or are soliciting lead plaintiffs; several allege omissions of inconsistent trial data — these coordinated filings raise settlement and defense‑cost risk. Examples: Wolf Haldenstein notice Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately, Levi & Korsinsky investor alert alleging omitted trial data ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit

Wall Street Analyst Weigh In

A number of analysts recently commented on ALDX shares. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price objective (down from $10.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, March 18th. BTIG Research reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, March 17th. Finally, Wall Street Zen lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.50.

Aldeyra Therapeutics Stock Down 1.3%

The firm has a market cap of $91.47 million, a price-to-earnings ratio of -2.67 and a beta of 1.34. The business has a 50 day moving average of $4.05 and a 200 day moving average of $4.69.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. Research analysts predict that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.

Insider Transactions at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, Director Richard Douglas purchased 70,000 shares of the firm’s stock in a transaction on Thursday, March 19th. The shares were purchased at an average cost of $1.40 per share, with a total value of $98,000.00. Following the purchase, the director owned 195,000 shares in the company, valued at approximately $273,000. This represents a 56.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 9.60% of the company’s stock.

Institutional Trading of Aldeyra Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Aldeyra Therapeutics by 2.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,591,869 shares of the biotechnology company’s stock worth $18,750,000 after buying an additional 90,276 shares during the last quarter. 683 Capital Management LLC boosted its stake in Aldeyra Therapeutics by 86.6% in the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock worth $7,925,000 after buying an additional 710,000 shares during the last quarter. AQR Capital Management LLC boosted its stake in Aldeyra Therapeutics by 275.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock worth $5,645,000 after buying an additional 1,081,257 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in Aldeyra Therapeutics by 12.9% in the 4th quarter. Kennedy Capital Management LLC now owns 1,255,838 shares of the biotechnology company’s stock worth $6,505,000 after buying an additional 143,625 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Aldeyra Therapeutics by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock worth $4,392,000 after buying an additional 8,769 shares during the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.